These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

349 related articles for article (PubMed ID: 28577743)

  • 21. [Mineralocorticoid receptor antagonists: inhibition of the renin angiotensin system].
    Derer W; Dechend R; Müller DN
    MMW Fortschr Med; 2010 Feb; 152(6):48-9. PubMed ID: 20302183
    [No Abstract]   [Full Text] [Related]  

  • 22. Cardiovascular and kidney outcomes with finerenone in patients with type 2 diabetes and chronic kidney disease: the FIDELITY pooled analysis.
    Agarwal R; Filippatos G; Pitt B; Anker SD; Rossing P; Joseph A; Kolkhof P; Nowack C; Gebel M; Ruilope LM; Bakris GL;
    Eur Heart J; 2022 Feb; 43(6):474-484. PubMed ID: 35023547
    [TBL] [Abstract][Full Text] [Related]  

  • 23. Finerenone: First Approval.
    Frampton JE
    Drugs; 2021 Oct; 81(15):1787-1794. PubMed ID: 34519996
    [TBL] [Abstract][Full Text] [Related]  

  • 24. [Finerenone: a new step on the way to nephroprotection].
    Delanaye P; De Seigneux S
    Rev Med Suisse; 2022 Aug; 18(792):1534-1538. PubMed ID: 36004652
    [TBL] [Abstract][Full Text] [Related]  

  • 25. Nonsteroidal Mineralocorticoid Receptor Antagonist Finerenone Improves Diastolic Dysfunction in Preclinical Nondiabetic Chronic Kidney Disease.
    Lima Posada I; Soulié M; Stephan Y; Palacios Ramirez R; Bonnard B; Nicol L; Pitt B; Kolkhof P; Mulder P; Jaisser F
    J Am Heart Assoc; 2024 Jun; 13(12):e032971. PubMed ID: 38842271
    [TBL] [Abstract][Full Text] [Related]  

  • 26. Non-steroidal mineralocorticoid receptor antagonists in cardiorenal disease.
    Pandey AK; Bhatt DL; Cosentino F; Marx N; Rotstein O; Pitt B; Pandey A; Butler J; Verma S
    Eur Heart J; 2022 Aug; 43(31):2931-2945. PubMed ID: 35713973
    [TBL] [Abstract][Full Text] [Related]  

  • 27. Selective aldosterone blockade with eplerenone reduces albuminuria in patients with type 2 diabetes.
    Epstein M; Williams GH; Weinberger M; Lewin A; Krause S; Mukherjee R; Patni R; Beckerman B
    Clin J Am Soc Nephrol; 2006 Sep; 1(5):940-51. PubMed ID: 17699311
    [TBL] [Abstract][Full Text] [Related]  

  • 28. Effect of Finerenone on Chronic Kidney Disease Outcomes in Type 2 Diabetes.
    Bakris GL; Agarwal R; Anker SD; Pitt B; Ruilope LM; Rossing P; Kolkhof P; Nowack C; Schloemer P; Joseph A; Filippatos G;
    N Engl J Med; 2020 Dec; 383(23):2219-2229. PubMed ID: 33264825
    [TBL] [Abstract][Full Text] [Related]  

  • 29. Finerenone and Cardiovascular Outcomes in Patients With Chronic Kidney Disease and Type 2 Diabetes.
    Filippatos G; Anker SD; Agarwal R; Pitt B; Ruilope LM; Rossing P; Kolkhof P; Schloemer P; Tornus I; Joseph A; Bakris GL;
    Circulation; 2021 Feb; 143(6):540-552. PubMed ID: 33198491
    [TBL] [Abstract][Full Text] [Related]  

  • 30. Direct Blood Pressure-Independent Anti-Fibrotic Effects by the Selective Nonsteroidal Mineralocorticoid Receptor Antagonist Finerenone in Progressive Models of Kidney Fibrosis.
    Droebner K; Pavkovic M; Grundmann M; Hartmann E; Goea L; Nordlohne J; Klar J; Eitner F; Kolkhof P
    Am J Nephrol; 2021; 52(7):588-601. PubMed ID: 34515038
    [TBL] [Abstract][Full Text] [Related]  

  • 31. Cardiorenal Benefits of Finerenone in Different Races and Kidney Function in Patients with Chronic Kidney Disease.
    Li P; Cui Y; Xu X; Dong J; Liao L
    Cardiorenal Med; 2024; 14(1):227-234. PubMed ID: 38537621
    [TBL] [Abstract][Full Text] [Related]  

  • 32. Renal Protection of Mineralocorticoid Receptor Antagonist, Finerenone, in Diabetic Kidney Disease.
    Kim DL; Lee SE; Kim NH
    Endocrinol Metab (Seoul); 2023 Feb; 38(1):43-55. PubMed ID: 36891650
    [TBL] [Abstract][Full Text] [Related]  

  • 33. Mineralocorticoid Receptor Antagonists: a Comprehensive Review of Finerenone.
    Rico-Mesa JS; White A; Ahmadian-Tehrani A; Anderson AS
    Curr Cardiol Rep; 2020 Sep; 22(11):140. PubMed ID: 32910349
    [TBL] [Abstract][Full Text] [Related]  

  • 34. Finerenone: a new mineralocorticoid receptor antagonist to beat chronic kidney disease.
    Raj R
    Curr Opin Nephrol Hypertens; 2022 May; 31(3):265-271. PubMed ID: 35165249
    [TBL] [Abstract][Full Text] [Related]  

  • 35. The use of a novel non-steroidal mineralocorticoid receptor antagonist finerenone for the treatment of chronic heart failure: A systematic review and meta-analysis.
    Pei H; Wang W; Zhao D; Wang L; Su GH; Zhao Z
    Medicine (Baltimore); 2018 Apr; 97(16):e0254. PubMed ID: 29668577
    [TBL] [Abstract][Full Text] [Related]  

  • 36. A Randomized Controlled Study of Finerenone vs. Eplerenone in Japanese Patients With Worsening Chronic Heart Failure and Diabetes and/or Chronic Kidney Disease.
    Sato N; Ajioka M; Yamada T; Kato M; Myoishi M; Yamada T; Kim SY; Nowack C; Kolkhof P; Shiga T;
    Circ J; 2016 Apr; 80(5):1113-22. PubMed ID: 27074824
    [TBL] [Abstract][Full Text] [Related]  

  • 37. Treatment with patiromer decreases aldosterone in patients with chronic kidney disease and hyperkalemia on renin-angiotensin system inhibitors.
    Weir MR; Bakris GL; Gross C; Mayo MR; Garza D; Stasiv Y; Yuan J; Berman L; Williams GH
    Kidney Int; 2016 Sep; 90(3):696-704. PubMed ID: 27350174
    [TBL] [Abstract][Full Text] [Related]  

  • 38. Efficacy and safety of finerenone for treatment of diabetic kidney disease: current knowledge and future perspective.
    Marzolla V; Infante M; Armani A; Rizzo M; Caprio M
    Expert Opin Drug Saf; 2022 Sep; 21(9):1161-1170. PubMed ID: 36174659
    [TBL] [Abstract][Full Text] [Related]  

  • 39. Nonsteroidal antagonists of the mineralocorticoid receptor.
    Kolkhof P; Nowack C; Eitner F
    Curr Opin Nephrol Hypertens; 2015 Sep; 24(5):417-24. PubMed ID: 26083526
    [TBL] [Abstract][Full Text] [Related]  

  • 40. [Finerenone cardiorenal effects and its placement in treatment of chronic kidney disease in patients with type 2 diabetes mellitus: A review].
    Salukhov VV; Shamkhalova MS; Duganova AV
    Ter Arkh; 2023 Apr; 95(3):261-273. PubMed ID: 37167149
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 18.